COMP <GO>
CCEL vs NIVF // EV/EBITDA & P/E VALUATION
Cryo-Cell International Inc. (NYSE) VS. NewGenIvf Group Limited (Class A) (NASDAQ) • 15-METRIC TALLY: CCEL 4
— NIVF 0
■ METRIC PARITY
LAST: $5.19 (+1.17%) • MKT CAP: $41.8M
valuation
61.2x
LAST: $1.14 (-5.00%) • MKT CAP: $11.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CCEL VS. NIVF)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CCEL | NIVF | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | -32.80% | +51.00 | CCEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 61.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.55% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -13.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 7.73% | 0.00% | +7.73 | CCEL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.63 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.3 | 22.5 | +41.77 | CCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $41.8M | $11.3M | $30.5M | CCEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CCEL REV | NIVF REV | CCEL GROSS % | NIVF GROSS % | CCEL FCF | NIVF FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.7M | — | 20.2% | $5.2M | -$11.1M |
| FY 2024 | $0 | $5.4M | — | 33.6% | $3.6M | -$8.3M |
| FY 2023 | $0 | $5.1M | — | — | $8.9M | -$1.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CCEL // BETA —
NIVF // BETA —